PMID- 15366678
OWN - NLM
STAT- MEDLINE
DCOM- 20050414
LR  - 20201105
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 28 Spec No 3
DP  - 2004 Apr
TI  - [Curative and preventive treatment of NSAID-associated gastroduodenal ulcers].
PG  - C77-83
AB  - The use of treatments to heal or to prevent nonsteroidal anti-inflammatory drugs 
      (NSAIDs) associated gastroduodenal lesions is based on replacement of mucosal 
      prostaglandin deficiency or inhibition of acid secretion. Four-week acid 
      suppression by proton pump inhibitors (PPI) with 7-day eradication triple therapy 
      in Helicobacter pylori positive patients is effective in healing gastric and 
      duodenal ulcer upon discontinuation of NSAIDs. In the event NSAIDs must be 
      continued, PPIs (omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg) are 
      more effective than H2-blockers and cytoprotective agents (sucralfate, 
      misoprostol) to heal mucosal lesions. In long-term prevention studies, omeprazole 
      20 mg, lansoprazole 15 mg, and pantoprazole 20 mg significantly reduce gastric 
      and duodenal ulcer rates. Misoprostol 800 microg is as effective as PPIs for 
      preventing symptomatic and complicated gastric ulcers, but less effective to 
      prevent duodenal ulcer, with a high rate of adverse effects such as diarrhea. 
      Helicobacter pylori eradication in infected patients decrease the risk of 
      NSAIDs-associated lesions but is less effective than concomitant antisecretory 
      treatment. Current data from comparative studies of PPIs vs ranitidine or 
      misoprostol are in favor of the PPIs as well tolerated and effective drugs in the 
      prophylaxis of NSAIDs-related gastroduodenal lesions in high-risk patients.
FAU - Dupas, Jean-Louis
AU  - Dupas JL
AD  - Service d'Hepato-Gastroenterologie, CHU Hopital Nord, 80054 Amiens Cedex. 
      dupas.jean-louis@chu-amiens.fr
FAU - Grigy, Claire
AU  - Grigy C
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Traitements curatif et preventif des ulceres gastro-duodenaux induits par les 
      AINS.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0E43V0BB57 (Misoprostol)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Humans
MH  - Misoprostol/therapeutic use
MH  - Peptic Ulcer/chemically induced/*drug therapy/*prevention & control
MH  - Proton Pump Inhibitors
RF  - 59
EDAT- 2004/09/16 05:00
MHDA- 2005/04/15 09:00
CRDT- 2004/09/16 05:00
PHST- 2004/09/16 05:00 [pubmed]
PHST- 2005/04/15 09:00 [medline]
PHST- 2004/09/16 05:00 [entrez]
AID - s0399-8320(04)95282-7 [pii]
AID - 10.1016/s0399-8320(04)95282-7 [doi]
PST - ppublish
SO  - Gastroenterol Clin Biol. 2004 Apr;28 Spec No 3:C77-83. doi: 
      10.1016/s0399-8320(04)95282-7.